Sainte-Foy-lès-Lyon, France
Sainte-Foy-lès-Lyon, France

Time filter

Source Type

Grant
Agency: Cordis | Branch: FP7 | Program: CSA-CA | Phase: KBBE.2010.1.3-05 | Award Amount: 1.21M | Year: 2010

This European surveillance network for influenza in pigs (ESNIP) 3 will maintain and expand surveillance networks established during previous EC concerted actions (ESNIP 1, QLK2-CT-2000-01636; ESNIP 2, SSPE-022749). Three work packages (WP 2, 3, 4) aim to increase the knowledge of the epidemiology and evolution of swine influenza (SI) virus (SIV) in European pigs through organised field surveillance programmes (WP2). Virus strains detected in these programmes will be subjected to detailed characterisation both antigenically (WP3) and genetically (WP4) using standardised methodology. Specifically this will involve timely information on genomic data and generation of antigenic maps using the latest technology. These analyses will provide significant and timely added value to knowledge of SIV. A strong focus will be monitoring spread and independent evolution of pandemic H1N1 2009 virus in pigs. All these data will in turn be used to improve the diagnosis of SI by updating the reagents used in the recommended techniques (WP2). The virus bank and electronic database that were established during ESNIPs 1 and 2 will also be expanded and formally curated with relevant SIV isolates and information for global dissemination within and outwith the consortium (WP5). ESNIP 3 represents the only organised surveillance network for influenza in pigs and seeks to strengthen formal interactions with human and avian surveillance networks previously established in ESNIP 2. A timely and transparent interaction with these networks will be a key output. These approaches are entirely consistent with improved pandemic preparedness and planning for human influenza whilst providing an evidence base for decisions in relation to veterinary health. The project consortium consists of 24 participants, which contribute a blend of different specialisms and skills ensuring multi-disciplinary cutting-edge outputs. The vast majority of the partners are actively working with SIV including in a field setting. Twenty-one participants are from 11 EU member states, seven of which were actively involved in ESNIP 2. Co-operation with partners in China and North America will continue to promote a greater understanding of the epidemiology of SIVs at a global level.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-SICA | Phase: KBBE-2008-1-3-02 | Award Amount: 4.09M | Year: 2009

Foot-and-mouth disease (FMD) is one of the worlds most infectious diseases of livestock and continues to pose a significant threat to endemic and free regions alike. The impact of FMD on society and international trade is high, thereby demanding stringent prevention, surveillance and control plans taken up in crisis preparedness plans. On the other hand, there is a global increased demand for animal welfare and ethical considerations necessitating a decreased reliance on eradication of animals to control FMD virus (FMDV) spread, and on the use of animals for the regulatory testing of veterinary products. The project seeks to balance these apparently contracting viewpoints by addressing specific gaps in our knowledge on all aspects of FMD control to enable implementation of enhanced animal-sparing vaccine-based control strategies tailored to the needs of free and endemic settings. Consequently, four main objectives have been identified, including (i) the improvement of the quality of existing FMD vaccines and diagnostics, (ii) the refinement and replacement of in vivo FMD vaccine quality tests, (iii) the development of new generation FMD vaccines and diagnostics by applying cutting edge technologies, and (iv) the enhancement of our knowledge on FMDV spread and transmission following the use of high-potency monovalent or multivalent vaccines. The role of wildlife (buffalo, gazelles and wild boar) in FMDV maintenance and transmission will also be investigated. The project consists of seven different, yet interlinked, work packages (WP) each addressing one of the items listed in the Work Programme topic KBBE-2008-1-3-02, and led by renowned WP leaders with years of relevant experience in the field of FMD. As such, significant progress towards the objectives of the Communitys Animal Health Strategy (2007-2013), the European Technology Platform for Global Animal Health, and the Global Roadmap for improving the Tools to Control FMD in Endemic Settings will be achieved.


News Article | November 30, 2016
Site: www.PR.com

Animal Parasiticides Market Anticipated to Grow US$ 13,064.7 Mn by 2026 In this report, Persistence Market Research (PMR) offers a ten year forecast of the global animal parasiticides market between 2016 and 2026. New York, NY, November 30, 2016 --( The prime factors powering the demand for animal parasiticides are increasing awareness about animal healthcare, increasing demand of animal derived food products, growing concern about foodborne diseases and zoonotic diseases, growth in adoption of companion animals and increase in animal healthcare expenditure. However, a growing preference for vegetarian food and diet and a stringent approval process for animal parasiticides coupled with restrictions on the use of parasiticides in food producing animals are the restraints affecting the global animal parasiticides market. A key trend defining the market is that larger players are focused towards enhancing their geographical presence and expanding their customer base by entering into strategic mergers and acquisitions. Furthermore, huge investment from government organizations and private players for research and development activities is also a key trend of global animal parasiticides market. The market is segmented based on product type, animal type, distribution channel and region. Based on product type, the market is sub-segmented into Ectoparasiticides, Endoparasiticides and Endectocides. Among the product type segment, Endoparasiticides segment is expected to exhibit the highest revenue growth over the forecast period. The Endoparasiticides product type segment is expected to register a significant CAGR of 5.9% during the forecast period in terms of value. The Ectoparasiticides segment is projected to exhibit a CAGR of 5.7% over the forecast period in terms of value. The market has also been segmented by animal type into food producing animals and companion animals. The food producing animals segment is expected to be the largest over the forecast period, with the segment witnessing a CAGR of 6.2% during the forecast period. One of the key growth drivers for animal parasiticides market is the growing concern about foodborne and zoonotic diseases. This report assesses trends driving growth of each segment on the regional as well as country level and offers potential takeaways that could prove substantially useful to animal parasiticides manufacturers looking to enter the market. Western Europe market has been estimated to dominate the global animal parasiticides market, accounting for a maximum revenue share of the market by 2016 end. North America is expected to account for over 20.0% revenue share of the global animal parasiticides market by 2016 end. Among the emerging markets, APEJ is estimated to exhibit a significant CAGR of 6.4% over the forecast period, followed by the North America market, due to increasing awareness about animal healthcare and increasing demand for animal derived food products. Some of the key players in the global animal parasiticides market include Sanofi S.A. (Merial), Ceva Sante Animlae, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc. The report discusses individual strategies followed by these companies in terms of enhancing their product portfolio, creating new marketing techniques, mergers and acquisitions. The ‘Competitive Landscape’ is included to provide report audiences with a dashboard view and company share collectively. Browse Complete Report @ http://www.persistencemarketresearch.com/market-research/animal-parasiticide-market.asp New York, NY, November 30, 2016 --( PR.com )-- The global animal parasiticides market is estimated to register a promising CAGR of 5.9% over the forecast period, owing to numerous factors, about which PMR offers thorough insights and forecasts in this report. The global animal parasiticides market registered a value of US$ 6,976.2 Mn in 2015 and is anticipated to reach a market valuation of US$ 13,064.7 Mn by 2026.The prime factors powering the demand for animal parasiticides are increasing awareness about animal healthcare, increasing demand of animal derived food products, growing concern about foodborne diseases and zoonotic diseases, growth in adoption of companion animals and increase in animal healthcare expenditure. However, a growing preference for vegetarian food and diet and a stringent approval process for animal parasiticides coupled with restrictions on the use of parasiticides in food producing animals are the restraints affecting the global animal parasiticides market.A key trend defining the market is that larger players are focused towards enhancing their geographical presence and expanding their customer base by entering into strategic mergers and acquisitions. Furthermore, huge investment from government organizations and private players for research and development activities is also a key trend of global animal parasiticides market.The market is segmented based on product type, animal type, distribution channel and region. Based on product type, the market is sub-segmented into Ectoparasiticides, Endoparasiticides and Endectocides. Among the product type segment, Endoparasiticides segment is expected to exhibit the highest revenue growth over the forecast period. The Endoparasiticides product type segment is expected to register a significant CAGR of 5.9% during the forecast period in terms of value. The Ectoparasiticides segment is projected to exhibit a CAGR of 5.7% over the forecast period in terms of value.The market has also been segmented by animal type into food producing animals and companion animals. The food producing animals segment is expected to be the largest over the forecast period, with the segment witnessing a CAGR of 6.2% during the forecast period. One of the key growth drivers for animal parasiticides market is the growing concern about foodborne and zoonotic diseases.This report assesses trends driving growth of each segment on the regional as well as country level and offers potential takeaways that could prove substantially useful to animal parasiticides manufacturers looking to enter the market. Western Europe market has been estimated to dominate the global animal parasiticides market, accounting for a maximum revenue share of the market by 2016 end. North America is expected to account for over 20.0% revenue share of the global animal parasiticides market by 2016 end. Among the emerging markets, APEJ is estimated to exhibit a significant CAGR of 6.4% over the forecast period, followed by the North America market, due to increasing awareness about animal healthcare and increasing demand for animal derived food products.Some of the key players in the global animal parasiticides market include Sanofi S.A. (Merial), Ceva Sante Animlae, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc. The report discusses individual strategies followed by these companies in terms of enhancing their product portfolio, creating new marketing techniques, mergers and acquisitions. The ‘Competitive Landscape’ is included to provide report audiences with a dashboard view and company share collectively.Browse Complete Report @ http://www.persistencemarketresearch.com/market-research/animal-parasiticide-market.asp Click here to view the list of recent Press Releases from Persistence Market Research


News Article | November 25, 2016
Site: www.prnewswire.co.uk

Persistence Market Research (PMR) delivers key insights on the global animal parasiticides market in its published report, titled "Global Market Study on Animal Parasiticides: Pharmacies and Drug Stores Distribution Channel Segment Expected to Register High Revenue Growth Through 2026." In terms of revenue, the global animal parasiticides market is estimated to register a promising CAGR of 5.9% over the forecast period, owing to numerous factors, about which PMR offers thorough insights and forecasts in this report. The global animal parasiticides market registered a value of US$ 6,976.2 Mn in 2015. The prime factors powering the demand for animal parasiticides are increasing awareness about animal healthcare, increasing demand of animal derived food products, growing concern about foodborne diseases and zoonotic diseases, growth in adoption of companion animals and increase in animal healthcare expenditure. However, a growing preference for vegetarian food and diet and a stringent approval process for animal parasiticides coupled with restrictions on the use of parasiticides in food producing animals are the restraints affecting the global animal parasiticides market. A key trend defining the market is that larger players are focused towards enhancing their geographical presence and expanding their customer base by entering into strategic mergers and acquisitions. Furthermore, huge investment from government organizations and private players for research and development activities is also a key trend of global animal parasiticides market. The market is segmented based on product type, animal type, distribution channel and region. Based on product type, the market is sub-segmented into Ectoparasiticides, Endoparasiticides and Endectocides. Among the product type segment, Endoparasiticides segment is expected to exhibit the highest revenue growth over the forecast period. The Endoparasiticides product type segment is expected to register a significant CAGR of 5.9% during the forecast period in terms of value. The Ectoparasiticides segment is projected to exhibit a CAGR of 5.7% over the forecast period in terms of value. The market has also been segmented by animal type into food producing animals and companion animals. The food producing animals segment is expected to be the largest over the forecast period, with the segment witnessing a CAGR of 6.2% during the forecast period. One of the key growth drivers for animal parasiticides market is the growing concern about foodborne and zoonotic diseases. This report assesses trends driving growth of each segment on the regional as well as country level and offers potential takeaways that could prove substantially useful to animal parasiticides manufacturers looking to enter the market. Western Europe market has been estimated to dominate the global animal parasiticides market, accounting for a maximum revenue share of the market by 2016 end. North America is expected to account for over 20.0% revenue share of the global animal parasiticides market by 2016 end. Among the emerging markets, APEJ is estimated to exhibit a significant CAGR of 6.4% over the forecast period, followed by the North America market, due to increasing awareness about animal healthcare and increasing demand for animal derived food products. Some of the key players in the global animal parasiticides market include Sanofi S.A. (Merial), Ceva Sante Animlae, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc. The report discusses individual strategies followed by these companies in terms of enhancing their product portfolio, creating new marketing techniques, mergers and acquisitions. The 'Competitive Landscape' is included to provide report audiences with a dashboard view and company share collectively. Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


Sanofi and Regeneron Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial will Continue as Planned Following Interim Analysis - ODYSSEY OUTCOMES trial1 is designed to prospectively assess the effect of Praluent on cardiovascular events in high-risk patients - Paris, France and Tarrytown, New York - November 17, 2016 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the ongoing Praluent® (alirocumab) ODYSSEY OUTCOMES trial will continue as planned, based on the recommendation of an independent Data Monitoring Committee (DMC) after it completed a second pre-specified interim analysis. The DMC will continue to monitor the ongoing safety and efficacy of Praluent as planned. The Phase 3, multi-center, randomized, double-blind, placebo-controlled ODYSSEY OUTCOMES trial involves more than 18,000 patients from 57 countries. All patients who entered the trial had experienced a heart attack or unstable angina requiring hospitalization within a year of entering the trial, and were unable to control their LDL cholesterol despite receiving maximally-tolerated statins and potentially other lipid-lowering therapies. Patients receiving maximally-tolerated statin therapy were randomized to receive either Praluent 75 milligrams (mg) every two weeks or placebo. Patients on Praluent had their dose increased to 150 mg every two weeks at week 8 if their LDL cholesterol remained above 50 milligrams/deciliter (mg/dL).1 About Praluent Praluent is a human monoclonal antibody that inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells, which results in lower LDL cholesterol levels in the blood. Praluent is the only PCSK9 inhibitor available in two dosages with two levels of efficacy (75 mg and 150 mg), allowing physicians to select the dose based on a patient's LDL cholesterol lowering needs. Praluent is currently approved in approximately 40 countries worldwide, including the U.S., Japan, Canada, Switzerland, Mexico, Brazil and the European Union (EU). In the U.S., Praluent is approved for use as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic CV disease, who require additional lowering of LDL cholesterol. In the E.U., Praluent is approved for the treatment of adult patients with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia as an adjunct to diet: a) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach their LDL cholesterol goals with the maximally-tolerated statin or b) alone or in combination with other lipid-lowering therapies for patients who are statin intolerant, or for whom a statin is contraindicated. The effect of Praluent on CV morbidity and mortality has not yet been determined. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. About Sanofi Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). About Regeneron Pharmaceuticals, Inc. Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter. Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of Praluent, or regarding potential future revenues from Praluent. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of Praluent; the absence of guarantee that Praluent will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to Praluent, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation, volatile economic conditions, and the impact of cost containment initiatives and subsequent changes thereto, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Regeneron Forward-Looking Statements and Use of Digital Media This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation Praluent® (alirocumab) Injection; unforeseen safety issues and possible liability resulting from the administration of products (including without limitation Praluent) and product candidates in patients; serious complications or side effects in connection with the use of Regeneron's products and product candidates in clinical trials, such as the ODYSSEY OUTCOMES trial discussed in this news release, which is prospectively assessing the potential of Praluent to demonstrate cardiovascular benefit; the timing of completion of the ODYSSEY OUTCOMES trial; coverage and reimbursement determinations by third-party payers, including Medicare, Medicaid, and pharmacy benefit management companies; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as Praluent), research and clinical programs, and business, including those relating to the enrollment, completion, and meeting of the relevant endpoints of post-approval studies (such as the ODYSSEY OUTCOMES trial); determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; risks associated with intellectual property of other parties and pending or future litigation relating thereto; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; and the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2015 and its Form 10-Q for the quarterly period ended September 30, 2016. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: KBBE-2009-1-3-02 | Award Amount: 4.15M | Year: 2010

The major outstanding challenges of orbivirus vaccine research is to develop vaccines that can afford a broad protective immune response against as many serotypes of each virus as possible, and to develop a high throughput DIVA assay (e.g. an ELISA). This project will use a coordinated multipartner approach to address these issues, to develop new experimental prototype vaccines and diagnostic approaches. It will build on specific expertise and reagents that are only available within the consortium and will link out to other international efforts in USA and South Africa to develop improved vaccines for these diseases. The consortium includes a number of industrial partners who are already active in vaccine manufacture for these and other veterinary diseases, in order to ensure that the findings of the research are transferred as soon as possible into commercial vaccines for European livestock. The project also includes two SMEs, who will be specifically involved in the development of DIVA compatible diagnostic tests. In summary, the specific objectives of the project will be: to develop multivalent vaccines using different approaches for Orbiviruses responsible for livestock diseases, in particular, Bluetongue Virus (BTV), African Horse Sickness Virus (AHSV) and Epizootic Haemorrhagic Disease Virus (EHDV); to understand the best vaccination strategy to elicit multi-serotype protection for these viruses in livestock and analyze immune responses for each of the novel vaccines developed for breadth of protection against multiple serotypes; and to develop DIVA compatible diagnostics that will work with the new vaccines developed in order to differentiate between vaccinated and infected animals.


News Article | February 21, 2017
Site: www.eurekalert.org

Johns Hopkins researchers say that in early pregnancy in mice with complete immune systems, Zika virus can cross the placenta -- intended to protect the developing fetus -- and appears to lead to a high percentage of miscarriages and to babies born with thin brain tissue and inflammation in brain cells. By administering Zika virus directly into the reproductive tract of pregnant mice that have an intact immune system, the researchers found that the Zika virus appears to create disorganization in the cellular layers of the placenta that keep toxins, bacteria and viruses from crossing. This disorganization could be how the virus penetrates the placenta to infect the fetus. The researchers also discovered a mechanism by which Zika may be keeping antiviral proteins in the body from doing their job of protecting cells from the virus. These findings, published Feb. 21 in Nature Communications, put scientists one step closer to developing targets for vaccines or other treatments for Zika. Currently there is no cure or treatment for the virus, which has been linked to serious neurological problems in infants whose mothers were exposed in early pregnancy. For much of 2016, Zika was considered a public health emergency by the World Health Organization. "We need to find a way to stop transmission of Zika through the placenta into the fetus, because that is where the damage is being done," says study co-leader Sabra L. Klein, PhD, an immunologist and microbiologist at the Johns Hopkins Bloomberg School of Public Health. "In the placentas of our mice, we're seeing a defense against Zika being mounted, but falling short, especially in early pregnancy, a time that corresponds to the first trimester in humans." Study co-leader Irina Burd, MD, PhD, a maternal/fetal medicine physician at Johns Hopkins Medicine, is hopeful that this is an important step toward halting the transmission of Zika from mother to child. "If we can determine what is happening, we may be able to find ways to minimize or even eliminate what can be devastating consequences for children of infected mothers," she says. For their research, the scientists developed a new mouse model that they say is uniquely capable of helping them to understand the mechanisms behind Zika transmission to the fetus. Unlike other mice used to study the virus, the Hopkins mice have completely intact immune systems more similar to humans, which enable researchers to see all that is involved in mounting an immune response. They intend to continue to follow up on their initial findings using the same model. To conduct this study, the researchers injected Zika virus directly into the reproductive tract of the pregnant mice during what would be the equivalent of the first trimester in a human. Since different species of animals may clear infections in different ways, they wanted to make sure the virus was getting to the most relevant tissues of the pregnant mice. The researchers used several different strains of the virus, using older strains - one from an outbreak in Nigeria in 1968 and another from Cambodia in 2010 - and contemporary ones from Brazil and Puerto Rico from the most recent epidemics. Nearly 94 percent of all pregnancies remained viable when a mock infection was introduced during the first trimester, while the viability of fetuses after Zika infection was reduced, regardless of which strain was used. Viability ranged from 56 percent from infection with the Brazil strain to 71 percent following infection with the Nigeria strain. That means anywhere from 29 to 44 percent of pregnancies were lost following infection. Since miscarriages can be caused by a multitude of factors, this Zika connection was not previously known. When the researchers infected the mice in the equivalent of the late second trimester instead, however, many fewer miscarriages occurred, suggesting that there is less vulnerability to Zika later in pregnancy. The researchers also could see the activation of antiviral defenses in the placentas of pregnant mice infected with virus. To cause an infection, viruses work like a lock and key, attaching to specific receptors on cells to take hold and spread. The researchers identified receptors on cells in the placenta that the virus may use to cross into the fetus. These anti-viral pathways could be potential targets for treatments that could stop transmission, the researchers say. The placenta is the key organ to a healthy pregnancy. It is typically organized into discrete layers of tissue. Under a microscope, the researchers found that the layers of tissue in the placentas of the mice infected with Zika virus were no longer organized well and might be how the virus could penetrate the fetus. "This could be why the fetuses in the Zika-infected mice were so vulnerable to either miscarriage or brain damage," Burd says. While the virus appeared to cross into the placenta fairly easily during the first trimester, the same was not true in the second trimester. As in humans, the direct effects on the pregnancy were much less pronounced if the infection occurred later in pregnancy. Those mouse pups born after an early infection were likely to have thinner cortexes and have inflammatory cells in the brain, while those born to mothers who had a later infection were much less likely to suffer those effects. In humans, Burd says, some babies born to mothers infected later are still showing some ill-effects, though it is unclear why. Since still so little is known about the long-term consequences of the Zika virus, in future experiments the researchers say they want to see if the siblings of the babies born during Zika infection will also suffer neurological effects. "We don't know if the effects persist in future pregnancies," Klein says. "We're just dealing with the here and now. We have no idea what the long-term consequences are for the mother." "Intrauterine Zika virus infection of pregnancy immunocompetent mice models transplacental transmission and adverse perinatal outcomes" was written by Meghan S. Vermillion; Jun Lei; Yahya Shabi; Victoria K. Baxter; Nathan P. Crilly; Michael McLane; Diane E. Griffin; Andrew Pekosz; Sabra L. Klein and Irina Burd. The research was supported by the Center for Emerging and Infectious Diseases at the Johns Hopkins Bloomberg School of Public Health; Medtronics Award from the Society for Women's Health Research; the Integrated Research Center for Fetal Medicine, the Sheikh Abdullah Bugshan Fund, the Merial Veterinary Scholars Fund and the National Institutes of Health's Training Veterinarians for Careers in Biomedical Research fund (T32 OD011089).


News Article | February 22, 2017
Site: www.futurity.org

Zika virus can penetrate the placenta in early pregnancy, causing miscarriages, studies with mice suggest. In addition, the virus—already known to cause a birth defect involving smaller-than-normal heads and brains—can also lead to babies born with thin brain tissue and inflammation in brain cells. The virus that causes the mosquito-borne disease appears to create disorganization in cellular layers of the placenta, layers meant to keep toxins, bacteria, and viruses from crossing from the mother to the fetus, researchers say. “We need to find a way to stop transmission of Zika through the placenta into the fetus, because that is where the damage is being done,” says study co-leader Sabra L. Klein, an immunologist and microbiologist at John Hopkins University’s Bloomberg School of Public Health. “In the placentas of our mice, we’re seeing a defense against Zika being mounted, but falling short, especially in early pregnancy, a time that corresponds to the first trimester in humans.” There is currently no cure or treatment for Zika, which causes relatively mild symptoms in most adults but potentially devastating consequences for developing fetuses whose mothers are infected. For much of 2016, Zika was considered a public health emergency by the World Health Organization, with outbreaks in South America and the Caribbean. Co-leader Irina Burd, a maternal/fetal medicine physician, is hopeful that the study, published in Nature Communications, is a step toward halting transmission of Zika from mother to child. “If we can determine what is happening, we may be able to find ways to minimize or even eliminate what can be devastating consequences for children of infected mothers.” Scientists developed a new mouse model they say is uniquely capable of helping them understand the mechanisms behind Zika transmission to the fetus. Unlike other mice used to study the virus, these have completely intact immune systems similar to that of humans, which allows researchers to see all that is involved in mounting an immune response. Researchers injected Zika virus directly into the reproductive tract of pregnant mice during the equivalent of the first trimester in a human. They used several strains of the virus, both older strains—one from an outbreak in Nigeria in 1968 and another from Cambodia in 2010—and strains from recent epidemics in Brazil and Puerto Rico. Nearly 94 percent of all pregnancies remained viable when a mock infection was introduced during the first trimester, but miscarriages rose significantly after Zika infection, no matter which strain was used. Viability ranged from 56 percent after infection with the Brazil strain to 71 percent with the Nigeria strain. That means anywhere from 29 to 44 percent of pregnancies were lost following infection. Since miscarriages have many causes, this Zika connection was not previously known. When the researchers infected the mice in the equivalent of the late second trimester, many fewer miscarriages occurred, suggesting that there is less vulnerability to Zika later in pregnancy. The placenta is the key organ to a healthy pregnancy. It is typically organized into discrete layers of tissue. Under a microscope, the researchers found that the placentas of the mice infected with Zika virus were no longer organized well. “This could be why the fetuses in the Zika-infected mice were so vulnerable to either miscarriage or brain damage,” Burd says. Those mouse pups who did not miscarry and were born after an early infection were likely to have thinner cortexes and have inflammatory cells in the brain, while those born to mothers who had a later infection were much less likely to suffer those effects. Support for the research came from the Center for Emerging and Infectious Diseases at the Johns Hopkins Bloomberg School of Public Health, the Society for Women’s Health Research, the Integrated Research Center for Fetal Medicine, the Sheikh Abdullah Bugshan Fund, the Merial Veterinary Scholars Fund, and the National Institutes of Health.


Grant
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-ITN-2008 | Award Amount: 2.86M | Year: 2009

In the context of global warming and globalisation, tick and tick-borne diseases (TTBD) are expected to emerge, with an increasing risk for animals and humans. It is imperative therefore to build up training capacities to improve integrated control measures, including the development of efficient and appropriate vaccines. The POSTICK ITN aims to (1) design new effective control strategies for TTBD diseases through understanding the mechanisms of tick-host-pathogen interactions regarding (i) pathogen diversity, survival and transmission, modulation of host immune response and tick survival and (ii) identification of host-pathogen-tick molecules for designing anti-tick vaccine and blocking pathogen transmission; (2) improve career perspectives of early-stage researchers (ESRs), broadening research competences through a strategic training programme consisting of (i) Research Training Packages including 14 individual PhD research projects and (ii) Complementary Training Modules including seminars, workshops, symposiums and a conference, combining the facilities and complementary expertise of 5 universities, 1 research institute and 2 industrial participants from 5 European countries and of 2 associated partners from Brazil and Israel. This ITN will be coordinated by the Ludwig-Maximilians-University, Germany, with a management structure including a steering committee and a supervisory board. The impact of the ITN lies on (i) a complementary research programme covering different areas of tick-pathogen-host interaction, (ii) an innovative training programme of high quality, (iii) improvement of existing collaborations between industry and research centre and universities, (iv) enhancement of the career prospects of ESRs, (v) contributing to European Community policies regarding the promotion of research and technology development, scientific cooperation and capacity building. Taken together, the impact of ITN and the results to be achieved are beyond the state of the art.


Global Foot and Mouth Disease (FMD) Vaccines Market Analysis: Animals, Vaccines, Growth Trends and Forecast to 2020, New Report by iHealthcareAnalyst, Inc. Foot and Mouth Disease (FMD) Vaccines Market by Animal Types (Cattle, Pigs, Sheep and Goats, Others) and FMD Vaccine Types (Conventional – Al(OH)3-based and Oil-based, and Emergency Vaccines) 2016-2020. Maryland Heights, MO, February 21, 2017 --( Browse Foot and Mouth Disease (FMD) Vaccines Market by Animal Types (Cattle, Pigs, Sheep and Goats, Others) and FMD Vaccine Types (Conventional – Al(OH)3-based and Oil-based, and Emergency Vaccines) 2016-2020 at https://www.ihealthcareanalyst.com/report/foot-and-mouth-disease-vaccines-market/. Foot and Mouth Disease (FMD) is caused by seven different types of serotypes: O, A, C, Asia 1 and Southern African Territories (SAT) 1, 2 and 3. The major symptoms of FMD are high fever, sudden weight loss, increased death rate in newborn animals, low conception rate, painful lesions in and around mouth, lips and feet, and excessive salivation. Cloven-hoofed animals especially cattle, pigs, sheep and goats are susceptible to FMD. Vaccination of susceptible animals against foot and mouth disease is a proven strategy for helping to combat the disease since the virus is highly infectious and can be spread by infected animals. The global foot and mouth disease vaccines market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market and also forecasts growth trends (CAGR% - 2016 to 2020). The report also covers the major companies operating in the market and provides detailed market analysis of the different animal types (cattle, pigs, sheep and goats, others) and FMD vaccine types (conventional – Al(OH)3-based and oil-based, and emergency vaccines) available in the global market. The global foot and mouth disease vaccines market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global foot and mouth disease vaccines market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global foot and mouth disease vaccines market and included in this report are Agrovet Co., Bayer AG, Biogenesis Bagó, Brilliant Bio Pharma Limited, Indian Immunologicals Ltd., Inova Biotechnologia, Intervac (Pvt.) Ltd., Merial, and Merck Animal Health (MSD). To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/foot-and-mouth-disease-vaccines-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, February 21, 2017 --( PR.com )-- The Foot and Mouth Disease Vaccines market is estimated to reach USD 800 Million in 2020, expanding at a CAGR of 4.6% from 2016 to 2020, due to increased demand for meat and dairy products worldwide. The FMD vaccines traditionally represents the largest share of the veterinary vaccine market worldwide in terms of sales of the entire livestock biological business.Browse Foot and Mouth Disease (FMD) Vaccines Market by Animal Types (Cattle, Pigs, Sheep and Goats, Others) and FMD Vaccine Types (Conventional – Al(OH)3-based and Oil-based, and Emergency Vaccines) 2016-2020 at https://www.ihealthcareanalyst.com/report/foot-and-mouth-disease-vaccines-market/.Foot and Mouth Disease (FMD) is caused by seven different types of serotypes: O, A, C, Asia 1 and Southern African Territories (SAT) 1, 2 and 3. The major symptoms of FMD are high fever, sudden weight loss, increased death rate in newborn animals, low conception rate, painful lesions in and around mouth, lips and feet, and excessive salivation. Cloven-hoofed animals especially cattle, pigs, sheep and goats are susceptible to FMD. Vaccination of susceptible animals against foot and mouth disease is a proven strategy for helping to combat the disease since the virus is highly infectious and can be spread by infected animals.The global foot and mouth disease vaccines market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market and also forecasts growth trends (CAGR% - 2016 to 2020). The report also covers the major companies operating in the market and provides detailed market analysis of the different animal types (cattle, pigs, sheep and goats, others) and FMD vaccine types (conventional – Al(OH)3-based and oil-based, and emergency vaccines) available in the global market. The global foot and mouth disease vaccines market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global foot and mouth disease vaccines market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global foot and mouth disease vaccines market and included in this report are Agrovet Co., Bayer AG, Biogenesis Bagó, Brilliant Bio Pharma Limited, Indian Immunologicals Ltd., Inova Biotechnologia, Intervac (Pvt.) Ltd., Merial, and Merck Animal Health (MSD).To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/foot-and-mouth-disease-vaccines-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill DriveMaryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com

Loading Merial SAS collaborators
Loading Merial SAS collaborators